Science 13 May 1994: Vol. 264. no. 5161, pp. 961 - 965 DOI: 10.1126/science.7513904

Prev | Table of Contents | Next

Articles

Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor {gamma} Is Mediated by Up-Regulation of B7H1.

L. Klotz, S. Hucke, D. Thimm, S. Classen, A. Gaarz, J. Schultze, F. Edenhofer, C. Kurts, T. Klockgether, A. Limmer, et al. (2009)
J. Immunol. 183, 129-136
 |  Abstract »  |  Full Text »  |  PDF »

Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes.

C. M. Long, H. W.M. van Laarhoven, J. W.M. Bulte, and H. I. Levitsky (2009)
Cancer Res. 69, 3180-3187
 |  Abstract »  |  Full Text »  |  PDF »

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.

C. Fonseca, R. Soiffer, V. Ho, M. Vanneman, M. Jinushi, J. Ritz, D. Neuberg, R. Stone, D. DeAngelo, and G. Dranoff (2009)
Blood 113, 1681-1688
 |  Abstract »  |  Full Text »  |  PDF »

Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma.

Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok (2008)
Cancer Res. 68, 9884-9891
 |  Abstract »  |  Full Text »  |  PDF »

Batf3 Deficiency Reveals a Critical Role for CD8{alpha}+ Dendritic Cells in Cytotoxic T Cell Immunity.

K. Hildner, B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, et al. (2008)
Science 322, 1097-1100
 |  Abstract »  |  Full Text »  |  PDF »

Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

J. Mouries, G. Moron, G. Schlecht, N. Escriou, G. Dadaglio, and C. Leclerc (2008)
Blood 112, 3713-3722
 |  Abstract »  |  Full Text »  |  PDF »

Primary CD8+ T-Cell Response to Soluble Ovalbumin Is Improved by Chloroquine Treatment In Vivo.

B. Garulli, M. G. Stillitano, V. Barnaba, and M. R. Castrucci (2008)
Clin. Vaccine Immunol. 15, 1497-1504
 |  Abstract »  |  Full Text »  |  PDF »

Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy.

B. Li, M. VanRoey, F. Triebel, and K. Jooss (2008)
Clin. Cancer Res. 14, 3545-3554
 |  Abstract »  |  Full Text »  |  PDF »

Loss of CTL Function among High-Avidity Tumor-Specific CD8+ T Cells following Tumor Infiltration.

C. N. Janicki, S. R. Jenkinson, N. A. Williams, and D. J. Morgan (2008)
Cancer Res. 68, 2993-3000
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector Vaccines.

G. Gasteiger, W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler (2007)
J. Virol. 81, 11925-11936
 |  Abstract »  |  Full Text »  |  PDF »

Calcineurin Inhibitors Block MHC-Restricted Antigen Presentation In Vivo.

Y.-H. Lee, Y.-R. Lee, S.-A Im, S.-I. Park, K.-H. Kim, T. Gerelchuluun, S. Song, K. Kim, and C.-K. Lee (2007)
J. Immunol. 179, 5711-5716
 |  Abstract »  |  Full Text »  |  PDF »

The B7 Family and Cancer Therapy: Costimulation and Coinhibition.

X. Zang and J. P. Allison (2007)
Clin. Cancer Res. 13, 5271-5279
 |  Abstract »  |  Full Text »  |  PDF »

Local Expression of Secondary Lymphoid Tissue Chemokine Delivered by Adeno-Associated Virus within the Tumor Bed Stimulates Strong Anti-Liver Tumor Immunity.

C.-m. Liang, C.-p. Zhong, R.-x. Sun, B.-b. Liu, C. Huang, J. Qin, S. Zhou, J. Shan, Y.-k. Liu, and S.-l. Ye (2007)
J. Virol. 81, 9502-9511
 |  Abstract »  |  Full Text »  |  PDF »

Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself.

J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy (2007)
J. Immunol. 179, 2493-2500
 |  Abstract »  |  Full Text »  |  PDF »

Decreased Tumor Surveillance after Adoptive T-Cell Therapy.

M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein (2007)
Cancer Res. 67, 7467-7476
 |  Abstract »  |  Full Text »  |  PDF »

Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells.

F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker (2007)
J. Immunol. 179, 845-853
 |  Abstract »  |  Full Text »  |  PDF »

CD4 cells can be more efficient at tumor rejection than CD8 cells.

A. Perez-Diez, N. T. Joncker, K. Choi, W. F. N. Chan, C. C. Anderson, O. Lantz, and P. Matzinger (2007)
Blood 109, 5346-5354
 |  Abstract »  |  Full Text »  |  PDF »

Distinct Pathways of Antigen Uptake and Intracellular Routing in CD4 and CD8 T Cell Activation.

S. Burgdorf, A. Kautz, V. Bohnert, P. A. Knolle, and C. Kurts (2007)
Science 316, 612-616
 |  Abstract »  |  Full Text »  |  PDF »

Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines.

U. Galili, K. Wigglesworth, and U. M. Abdel-Motal (2007)
J. Immunol. 178, 4676-4687
 |  Abstract »  |  Full Text »  |  PDF »

Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer.

M. J. Anderson, K. Shafer-Weaver, N. M. Greenberg, and A. A. Hurwitz (2007)
J. Immunol. 178, 1268-1276
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses.

D.-Y. Hou, A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn (2007)
Cancer Res. 67, 792-801
 |  Abstract »  |  Full Text »  |  PDF »

Dendritic Cells Cross-Dressed with Peptide MHC Class I Complexes Prime CD8+ T Cells.

B. P. Dolan, K. D. Gibbs Jr, and S. Ostrand-Rosenberg (2006)
J. Immunol. 177, 6018-6024
 |  Abstract »  |  Full Text »  |  PDF »

Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice..

P. J. Wysocki, E. P. Kwiatkowska, U. Kazimierczak, W. Suchorska, D. W. Kowalczyk, and A. Mackiewicz (2006)
Clin. Cancer Res. 12, 4095-4102
 |  Abstract »  |  Full Text »  |  PDF »

Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis.

K. Bennaceur, I. Popa, J. Portoukalian, O. Berthier-Vergnes, and J. Peguet-Navarro (2006)
Int. Immunol. 18, 879-886
 |  Abstract »  |  Full Text »  |  PDF »

Langerhans cells cross-present antigen derived from skin.

P. Stoitzner, C. H. Tripp, A. Eberhart, K. M. Price, J. Y. Jung, L. Bursch, F. Ronchese, and N. Romani (2006)
PNAS 103, 7783-7788
 |  Abstract »  |  Full Text »  |  PDF »

Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma..

S.-C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma (2006)
Cancer Res. 66, 3205-3213
 |  Abstract »  |  Full Text »  |  PDF »

Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity.

R. G. van der Most, A. Currie, B. W.S. Robinson, and R. A. Lake (2006)
Cancer Res. 66, 601-604
 |  Abstract »  |  Full Text »  |  PDF »

In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles.

Y. J. Kwon, E. James, N. Shastri, and J. M. J. Frechet (2005)
PNAS 102, 18264-18268
 |  Abstract »  |  Full Text »  |  PDF »

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.

K. Liu, J. Idoyaga, A. Charalambous, S.-i. Fujii, A. Bonito, J. Mordoh, R. Wainstok, X.-F. Bai, Y. Liu, and R. M. Steinman (2005)
J. Exp. Med. 202, 1507-1516
 |  Abstract »  |  Full Text »  |  PDF »

Identification of the Immunodominant HY H2-Dk Epitope and Evaluation of the Role of Direct and Indirect Antigen Presentation in HY Responses.

M. Millrain, D. Scott, C. Addey, H. Dewchand, P. Ellis, I. Ehrmann, M. Mitchell, P. Burgoyne, E. Simpson, and J. Dyson (2005)
J. Immunol. 175, 7209-7217
 |  Abstract »  |  Full Text »  |  PDF »

Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects.

C.-W. Liao, C.-A. Chen, C.-N. Lee, Y.-N. Su, M.-C. Chang, M.-H. Syu, C.-Y. Hsieh, and W.-F. Cheng (2005)
Cancer Res. 65, 9089-9098
 |  Abstract »  |  Full Text »  |  PDF »

Distinct and Overlapping Roles of Interleukin-10 and CD25+ Regulatory T Cells in the Inhibition of Antitumor CD8 T-Cell Responses.

C. Dercamp, K. Chemin, C. Caux, G. Trinchieri, and A. P. Vicari (2005)
Cancer Res. 65, 8479-8486
 |  Abstract »  |  Full Text »  |  PDF »

Both Dendritic Cells and Macrophages Can Stimulate Naive CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells.

L.-A. M. Pozzi, J. W. Maciaszek, and K. L. Rock (2005)
J. Immunol. 175, 2071-2081
 |  Abstract »  |  Full Text »  |  PDF »

B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.

S.-i. Hiraoka, N. Takeuchi, Y. Bian, H. Nakahara, M. Kogo, K. Dunussi-Joannopoulos, S. Wolf, S. Ono, and H. Fujiwara (2005)
Int. Immunol. 17, 1071-1079
 |  Abstract »  |  Full Text »  |  PDF »

Inefficient Cross-Presentation Limits the CD8+ T Cell Response to a Subdominant Tumor Antigen Epitope.

P. Otahal, S. C. Hutchinson, L. M. Mylin, M. J. Tevethia, S. S. Tevethia, and T. D. Schell (2005)
J. Immunol. 175, 700-712
 |  Abstract »  |  Full Text »  |  PDF »

{alpha}v{beta}3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.

E. Godefroy, A. Moreau-Aubry, E. Diez, B. Dreno, F. Jotereau, and Y. Guilloux (2005)
J. Exp. Med. 202, 61-72
 |  Abstract »  |  Full Text »  |  PDF »

An RNA Vaccine Based on Recombinant Semliki Forest Virus Particles Expressing the Cu,Zn Superoxide Dismutase Protein of Brucella abortus Induces Protective Immunity in BALB/c Mice.

A. A. Onate, G. Donoso, G. Moraga-Cid, H. Folch, S. Cespedes, and E. Andrews (2005)
Infect. Immun. 73, 3294-3300
 |  Abstract »  |  Full Text »  |  PDF »

Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells.

Y.-R. Lee, I.-H. Yang, Y.-H. Lee, S.-A Im, S. Song, H. Li, K. Han, K. Kim, S. K. Eo, and C.-K. Lee (2005)
Blood 105, 3951-3955
 |  Abstract »  |  Full Text »  |  PDF »

An Important Role of CD80/CD86-CTLA-4 Signaling during Photocarcinogenesis in Mice.

K. Loser, A. Scherer, M. B. W. Krummen, G. Varga, T. Higuchi, T. Schwarz, A. H. Sharpe, S. Grabbe, J. A. Bluestone, and S. Beissert (2005)
J. Immunol. 174, 5298-5305
 |  Abstract »  |  Full Text »  |  PDF »

Surrogate Tumor Antigen Vaccination Induces Tumor-Specific Immunity and the Rejection of Spontaneous Metastases.

J. D. Lewis, M. H. Shearer, R. C. Kennedy, and R. K. Bright (2005)
Cancer Res. 65, 2938-2946
 |  Abstract »  |  Full Text »  |  PDF »

The Role of Intercellular Adhesion Molecule-1/LFA-1 Interactions in the Generation of Tumor-Specific CD8+ T Cell Responses.

S. R. Jenkinson, N. A. Williams, and D. J. Morgan (2005)
J. Immunol. 174, 3401-3407
 |  Abstract »  |  Full Text »  |  PDF »

CTLA-4 Blockade: Unveiling Immune Regulation.

G. Dranoff (2005)
J. Clin. Oncol. 23, 662-664
 |  Full Text »  |  PDF »

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma.

K. Sanderson, R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, et al. (2005)
J. Clin. Oncol. 23, 741-750
 |  Abstract »  |  Full Text »  |  PDF »

Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors.

V. M. Moiseyenko, A. O. Danilov, I. A. Baldueva, A. B. Danilova, N. V. Tyukavina, S. S. Larin, S. L. Kiselev, R. V. Orlova, V. V. Anisimov, A. I. Semenova, et al. (2005)
Ann. Onc. 16, 162-168
 |  Abstract »  |  Full Text »  |  PDF »

Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells.

J. Imai, H. Hasegawa, M. Maruya, S. Koyasu, and I. Yahara (2005)
Int. Immunol. 17, 45-53
 |  Abstract »  |  Full Text »  |  PDF »

Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. coli and Research on Its In Vitro and In Vivo Bioactivity.

L. Chun, C.-C. Yin, J.-Z. Song, M.-X. Liu, J.-H. Piao, Q. Lin, X.-B. Wang, and H.-L. Huang (2004)
J. Biochem. 136, 769-776
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication.

G. J. D. van Mierlo, Z. F. H. M. Boonman, H. M. H. Dumortier, A. Th. den Boer, M. F. Fransen, J. Nouta, E. I. H. van der Voort, R. Offringa, R. E. M. Toes, and C. J. M. Melief (2004)
J. Immunol. 173, 6753-6759
 |  Abstract »  |  Full Text »  |  PDF »

Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor.

G. Driessens, M. Hamdane, V. Cool, T. Velu, and C. Bruyns (2004)
Cancer Res. 64, 8435-8442
 |  Abstract »  |  Full Text »  |  PDF »

Cutting Edge: Cross-Presentation of Cell-Associated Antigens to MHC Class I Molecule Is Regulated by a Major Transcription Factor for Heat Shock Proteins.

H. Zheng and Z. Li (2004)
J. Immunol. 173, 5929-5933
 |  Abstract »  |  Full Text »  |  PDF »

Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R).

E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. (2004)
J. Immunol. 173, 6472-6480
 |  Abstract »  |  Full Text »  |  PDF »

Anti-HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice.

N. Takeuchi, S.-i. Hiraoka, X.-Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara (2004)
Cancer Res. 64, 7588-7595
 |  Abstract »  |  Full Text »  |  PDF »

Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine.

Y.-F. He, G.-M. Zhang, X.-H. Wang, H. Zhang, Y. Yuan, D. Li, and Z.-H. Feng (2004)
J. Immunol. 173, 4919-4928
 |  Abstract »  |  Full Text »  |  PDF »

High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma.

N. Meidenbauer, A. Zippelius, M. J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, F.-A. L. Gal, et al. (2004)
Cancer Res. 64, 6319-6326
 |  Abstract »  |  Full Text »  |  PDF »

High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells.

P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello (2004)
Cancer Res. 64, 6337-6343
 |  Abstract »  |  Full Text »  |  PDF »

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells.

G. Ratzinger, J. Baggers, M. A. de Cos, J. Yuan, T. Dao, J. L. Reagan, C. Munz, G. Heller, and J. W. Young (2004)
J. Immunol. 173, 2780-2791
 |  Abstract »  |  Full Text »  |  PDF »

Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients.

A. M. Thomas, L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y.-C. Chen, L.-Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee (2004)
J. Exp. Med. 200, 297-306
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Immunotherapy: A Treatment for the Masses.

J. N. Blattman and P. D. Greenberg (2004)
Science 305, 200-205
 |  Abstract »  |  Full Text »  |  PDF »

Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion.

Y. Tanaka, S. Koido, J. Xia, M. Ohana, C. Liu, G. M. Cote, D. B. Sawyer, S. Calderwood, and J. Gong (2004)
J. Immunol. 172, 7848-7858
 |  Abstract »  |  Full Text »  |  PDF »

Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.

C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik (2004)
Blood 103, 4353-4361
 |  Abstract »  |  Full Text »  |  PDF »

Antigen Bias in T Cell Cross-Priming.

M. C. Wolkers, N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. M. Schumacher (2004)
Science 304, 1314-1317
 |  Abstract »  |  Full Text »  |  PDF »

Loading of MHC Class I and II Presentation Pathways by Exogenous Antigens: A Quantitative In Vivo Comparison.

T. Storni and M. F. Bachmann (2004)
J. Immunol. 172, 6129-6135
 |  Abstract »  |  Full Text »  |  PDF »

Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity.

S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al. (2004)
Clin. Cancer Res. 10, 2891-2901
 |  Abstract »  |  Full Text »  |  PDF »

Cellular protein is the source of cross-priming antigen in vivo.

L. Shen and K. L. Rock (2004)
PNAS 101, 3035-3040
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy.

S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg (2004)
Cancer Res. 64, 1867-1874
 |  Abstract »  |  Full Text »  |  PDF »

Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens.

A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor (2003)
Cancer Res. 63, 9007-9015
 |  Abstract »  |  Full Text »  |  PDF »

EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-{gamma}-Dependent Antitumor Responses in a Lung Cancer Model.

S. Hillinger, S.-C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma (2003)
J. Immunol. 171, 6457-6465
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Priming of Diabetogenic T Cells Dissociated from CTL-Induced Shedding of {beta} Cell Autoantigens.

J. Yamanouchi, J. Verdaguer, B. Han, A. Amrani, P. Serra, and P. Santamaria (2003)
J. Immunol. 171, 6900-6909
 |  Abstract »  |  Full Text »  |  PDF »

Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies.

O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero (2003)
Clin. Cancer Res. 9, 5454-5464
 |  Abstract »  |  Full Text »  |  PDF »

IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2.

C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson (2003)
J. Immunol. 171, 5051-5063
 |  Abstract »  |  Full Text »  |  PDF »

Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host Dendritic Cells.

A. Schneeberger, P. Luhrs, R. Kutil, P. Steinlein, H. Schild, W. Schmidt, and G. Stingl (2003)
J. Immunol. 171, 5180-5187
 |  Abstract »  |  Full Text »  |  PDF »

Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer.

C. Moon, Y. Oh, and J. A. Roth (2003)
Clin. Cancer Res. 9, 5055-5067
 |  Abstract »  |  Full Text »  |  PDF »

DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA.

K. Devaraj, M. L. Gillison, and T.-C. Wu (2003)
Critical Reviews in Oral Biology & Medicine 14, 345-362
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma.

R. Soiffer, F. S. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. Mentzer, M. Jaklitsch, et al. (2003)
J. Clin. Oncol. 21, 3343-3350
 |  Abstract »  |  Full Text »  |  PDF »

Cutting Edge: Cross-Presentation as a Mechanism for Efficient Recruitment of Tumor-Specific CTL to the Brain.

T. Calzascia, W. Di Berardino-Besson, R. Wilmotte, F. Masson, N. d. Tribolet, P.-Y. Dietrich, and P. R. Walker (2003)
J. Immunol. 171, 2187-2191
 |  Abstract »  |  Full Text »  |  PDF »

A Critical Requirement of Interferon {gamma}-mediated Angiostasis for Tumor Rejection by CD8+ T Cells.

Z. Qin, J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, and T. Blankenstein (2003)
Cancer Res. 63, 4095-4100
 |  Abstract »  |  Full Text »  |  PDF »

Current Developments in Cancer Vaccines and Cellular Immunotherapy.

A. Ribas, L. H. Butterfield, J. A. Glaspy, and J. S. Economou (2003)
J. Clin. Oncol. 21, 2415-2432
 |  Abstract »  |  Full Text »  |  PDF »

Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells.

T. Schuler and T. Blankenstein (2003)
J. Immunol. 170, 4427-4431
 |  Abstract »  |  Full Text »  |  PDF »

Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells.

P. Yu, M. T. Spiotto, Y. Lee, H. Schreiber, and Y.-X. Fu (2003)
J. Exp. Med. 197, 985-995
 |  Abstract »  |  Full Text »  |  PDF »

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

F. S. Hodi, M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. (2003)
PNAS 100, 4712-4717
 |  Abstract »  |  Full Text »  |  PDF »

A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells.

S. K. Datta, V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, et al. (2003)
J. Immunol. 170, 4102-4110
 |  Abstract »  |  Full Text »  |  PDF »

Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis.

J. Peguet-Navarro, M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian (2003)
J. Immunol. 170, 3488-3494
 |  Abstract »  |  Full Text »  |  PDF »

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

J. C. Schmollinger, R. H. Vonderheide, K. M. Hoar, B. Maecker, J. L. Schultze, F. S. Hodi, R. J. Soiffer, K. Jung, M. J. Kuroda, N. L. Letvin, et al. (2003)
PNAS 100, 3398-3403
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Cyclooxygenase 2-dependent Suppression of Dendritic Cell Function.

S. Sharma, M. Stolina, S.-C. Yang, F. Baratelli, J. F. Lin, K. Atianzar, J. Luo, L. Zhu, Y. Lin, M. Huang, et al. (2003)
Clin. Cancer Res. 9, 961-968
 |  Abstract »  |  Full Text »  |  PDF »

Determinant Spreading Associated with Clinical Response in Dendritic Cell-based Immunotherapy for Malignant Melanoma.

L. H. Butterfield, A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H.-J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al. (2003)
Clin. Cancer Res. 9, 998-1008
 |  Abstract »  |  Full Text »  |  PDF »

Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma.

R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, et al. (2003)
J. Clin. Oncol. 21, 624-630
 |  Abstract »  |  Full Text »  |  PDF »

Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma.

A. Curti, M. Parenza, and M. P. Colombo (2003)
Blood 101, 568-575
 |  Abstract »  |  Full Text »  |  PDF »

CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8+ T Cells.

H.-M. Hu, H. Winter, J. Ma, M. Croft, W. J. Urba, and B. A. Fox (2002)
J. Immunol. 169, 4897-4904
 |  Abstract »  |  Full Text »  |  PDF »

Direct Priming and Cross-Priming Contribute Differentially to the Induction of CD8+ CTL Following Exposure to Vaccinia Virus Via Different Routes.

X. Shen, S. B. J. Wong, C. B. Buck, J. Zhang, and R. F. Siliciano (2002)
J. Immunol. 169, 4222-4229
 |  Abstract »  |  Full Text »  |  PDF »

Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion.

E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al. (2002)
Cancer Res. 62, 5495-5504
 |  Abstract »  |  Full Text »  |  PDF »

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato (2002)
PNAS 99, 12293-12297
 |  Abstract »  |  Full Text »  |  PDF »

Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8- Dendritic Cells In Vivo.

J. M.M. den Haan and M. J. Bevan (2002)
J. Exp. Med. 196, 817-827
 |  Abstract »  |  Full Text »  |  PDF »

Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells.

M. Mohty, D. Isnardon, A. Charbonnier, M. Lafage-Pochitaloff, M. Merlin, D. Sainty, D. Olive, and B. Gaugler (2002)
Int. Immunol. 14, 741-750
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles.

D. Marsac, D. Loirat, C. Petit, O. Schwartz, and M.-L. Michel (2002)
J. Virol. 76, 7544-7553
 |  Abstract »  |  Full Text »  |  PDF »

Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells.

G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner (2002)
Blood 100, 200-207
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?.

G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini (2002)
J Natl Cancer Inst 94, 805-818
 |  Abstract »  |  Full Text »  |  PDF »

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.

F. S. Hodi, J. C. Schmollinger, R. J. Soiffer, R. Salgia, T. Lynch, J. Ritz, E. P. Alyea, J. Yang, D. Neuberg, M. Mihm, et al. (2002)
PNAS 99, 6919-6924
 |  Abstract »  |  Full Text »  |  PDF »

Soluble proteins and haptens on bone marrow-derived dendritic cells are presented to host CD4 T cells in an MHC-restricted manner.

E. B. Olasz, J. Linton, and S. I. Katz (2002)
Int. Immunol. 14, 493-502
 |  Abstract »  |  Full Text »  |  PDF »

Increased Tumorigenicity, but Unchanged Immunogenicity, of Transporter for Antigen Presentation 1-deficient Tumors.

Z. Qin, C. Harders, X. Cao, C. Huber, T. Blankenstein, and B. Seliger (2002)
Cancer Res. 62, 2856-2860
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products